These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19414790)

  • 41. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.
    Hong PW; Nguyen S; Young S; Su SV; Lee B
    J Virol; 2007 Aug; 81(15):8325-36. PubMed ID: 17522223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epitope located N-glycans impair the MHC-I epitope generation and presentation.
    Chiritoiu GN; Jandus C; Munteanu CV; Ghenea S; Gannon PO; Romero P; Petrescu SM
    Electrophoresis; 2016 Jun; 37(11):1448-60. PubMed ID: 26701645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins.
    Biller M; Bolmstedt A; Hemming A; Olofsson S
    J Virol Methods; 1998 Dec; 76(1-2):87-100. PubMed ID: 9923743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
    Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
    Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
    Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH
    J Immunol; 1995 Feb; 154(4):1973-86. PubMed ID: 7530749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
    Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
    J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
    SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
    J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition.
    Fernandez MH; Faith A; Higgins JA; Weber J; Rees AD
    Immunology; 1995 Jun; 85(2):176-83. PubMed ID: 7642208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations in the D strand of the human CD4 V1 domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly.
    Piatier-Tonneau D; Gastinel LN; Moussy G; Bénichou B; Amblard F; Vaigot P; Auffray C
    Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6858-62. PubMed ID: 1713692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.
    Hager-Braun C; Hochleitner EO; Gorny MK; Zolla-Pazner S; Bienstock RJ; Tomer KB
    J Am Soc Mass Spectrom; 2010 Oct; 21(10):1687-98. PubMed ID: 20434359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibility complex molecules.
    Bowman MR; MacFerrin KD; Schreiber SL; Burakoff SJ
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):9052-6. PubMed ID: 1978941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
    Trujillo JR; Rogers RA; Brain JD
    Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV.
    Balzarini J
    Lancet Infect Dis; 2005 Nov; 5(11):726-31. PubMed ID: 16253890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
    Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficient in vivo presentation of Listeria monocytogenes- derived CD4 and CD8 T cell epitopes in the absence of IFN-gamma.
    Skoberne M; Geginat G
    J Immunol; 2002 Feb; 168(4):1854-60. PubMed ID: 11823519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.